Reproductive endocrinology and infertility

ACFS Announces the Arrival of Dr. Evan Reshef as a New Member of its Fertility Team

Retrieved on: 
Tuesday, December 19, 2023

PHOENIX, Dec. 19, 2023 /PRNewswire-PRWeb/ -- Arizona Center for Fertility Studies (ACFS) is pleased to announce that Dr. Evan Reshef has joined its team of fertility specialists. With his background in Reproductive Endocrinology and Infertility, Dr. Reshef returns to Arizona, bringing valuable experience to the center.

Key Points: 
  • PHOENIX, Dec. 19, 2023 /PRNewswire-PRWeb/ -- Arizona Center for Fertility Studies (ACFS) is pleased to announce that Dr. Evan Reshef has joined its team of fertility specialists.
  • With his background in Reproductive Endocrinology and Infertility, Dr. Reshef returns to Arizona, bringing valuable experience to the center.
  • "I am dedicated to providing thoughtful care and supporting our patients at ACFS," said Dr. Reshef.
  • ACFS, known for its personalized fertility treatments, welcomes Dr. Reshef as part of its ongoing effort to enhance its services.

Clinics within The Prelude Network ® Recognized by the Society for Assisted Reproductive Technology for Excellence in Fertility Care Services and Reporting

Retrieved on: 
Tuesday, November 7, 2023

HOUSTON, Nov. 7, 2023 /PRNewswire/ -- The Prelude Network®, the largest network of fertility clinics in North America, announces today that two of its clinics have been recognized by the Society for Assisted Reproductive Technology (SART), with Reproductive Biology Associates (RBA) in Atlanta, Georgia receiving a SART Platinum designation and IVFMD in Miami, Florida receiving a SART Gold designation.

Key Points: 
  • HOUSTON, Nov. 7, 2023 /PRNewswire/ -- The Prelude Network ®, the largest network of fertility clinics in North America, announces today that two of its clinics have been recognized by the Society for Assisted Reproductive Technology (SART), with Reproductive Biology Associates (RBA) in Atlanta, Georgia receiving a SART Platinum designation and IVFMD in Miami, Florida receiving a SART Gold designation.
  • This recognition is a joint selection by SART's Quality Assurance and Validation Committees to recognize clinics for their excellence in prospective reporting and for following guidance set forth by the American Society for Reproductive Medicine (ASRM) and SART.
  • "It is a testament of their dedication to patients and the field of reproductive medicine to uphold, practice, and deliver the highest standards in fertility care."
  • The clinic provides patient-centric, individualized care that offers patients the latest science and technologies in fertility medicine.

Military Families Campaign Raises Awareness of Infertility in the Military Community, Expands Access to Quality Care to Veterans and Active-Duty Service Members

Retrieved on: 
Wednesday, November 1, 2023

HOUSTON, Nov. 1, 2023 /PRNewswire/ -- In celebration of National Veteran and Military Families Month  The Prelude Network® (Prelude) honors the members of the US Armed Forces by expanding accessibility to premium reproductive services to veterans and active-duty personnel through its Military Families Month campaign.

Key Points: 
  • HOUSTON, Nov. 1, 2023 /PRNewswire/ -- In celebration of National Veteran and Military Families Month The Prelude Network ® (Prelude) honors the members of the US Armed Forces by expanding accessibility to premium reproductive services to veterans and active-duty personnel through its Military Families Month campaign.
  • Historically, accessing fertility services has been limited for service members as they must meet stringent criteria set by the Department of Veterans Affairs (VA).
  • "Through our Military Families campaign, Inception is doing its part honor, serve, and support our military members by helping improve that accessibility."
  • For active and retired service members interested in learning more about Prelude's Military Families Month offer, please visit Prelude's Military Families Campaign page.

HRC Fertility Center Adds Hakman and Wertheimer to Roster of Award-Winning Physicians

Retrieved on: 
Thursday, September 28, 2023

HRC Fertility Center , one of the largest providers of advanced fertility treatments based in Southern California, today announced the addition of Sasha Hakman, MD and Sahar Wertheimer, MD , to its team of award-winning physicians.

Key Points: 
  • HRC Fertility Center , one of the largest providers of advanced fertility treatments based in Southern California, today announced the addition of Sasha Hakman, MD and Sahar Wertheimer, MD , to its team of award-winning physicians.
  • Effective immediately, Dr. Hakman and Dr. Wertheimer, both highly sought-after Reproductive Endocrinologist and Infertility Specialists, have joined the center’s West Los Angeles office.
  • Dr. Hakman has a longstanding family and personal history of infertility and Polycystic Ovary Syndrome (PCOS).
  • Dr. Hakman is a subject matter expert for the American Board of OB-GYN, and serves as HRC Fertility’s baby center medical advisor.

Innovation Fertility and Sunfish Launch a Groundbreaking Program to Reduce the Financial Stress of In Vitro Fertilization for Aspiring Parents

Retrieved on: 
Tuesday, September 12, 2023

The two are jointly launching Sunfish's new Gold Membership Program, which uses proprietary analytics to develop custom financial plans to cover in vitro fertilization (IVF) treatments for individual patients.

Key Points: 
  • The two are jointly launching Sunfish's new Gold Membership Program, which uses proprietary analytics to develop custom financial plans to cover in vitro fertilization (IVF) treatments for individual patients.
  • Innovation Fertility is launching this new program for patients at several clinics nationwide, including RMA Michigan, Reproductive Specialists of the Carolinas, and Billings Clinic.
  • The Sunfish Gold Membership Program will help reduce patients' financial burden and uncertainty while seeking fertility care, which is revolutionary in the fertility industry," states Dwight Ryan, CEO of Innovation Fertility.
  • Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals with the support of some of the premier reproductive endocrinologists.

Fertilix Proven Effective in Blocking Damage From Low-Dose Exposure to Chemicals Commonly Found in Plastic Consumer Products

Retrieved on: 
Thursday, May 18, 2023

The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF.

Key Points: 
  • The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF.
  • These chemicals have long been linked to lowering male fertility, but the novelty of this study was in evaluating doses that were previously considered safe or inconsequential for consumers.
  • Interestingly, the study also showed that co-administration with micronutrient supplement Fertilix(R) significantly blocked the damaging effects of these chemicals on sperm DNA.
  • This study is now available with open-access in Antioxidants, a premier journal in antioxidant research, and can be downloaded here.

The Future of Fertility Financing: How Sunfish is changing the fertility industry to focus on successful pregnancies, not treatments

Retrieved on: 
Thursday, August 3, 2023

Sunfish announces today that it has launched a new year-long membership program, which includes a custom financial plan with IVF treatment package costs for each member.

Key Points: 
  • Sunfish announces today that it has launched a new year-long membership program, which includes a custom financial plan with IVF treatment package costs for each member.
  • What's groundbreaking: this membership guarantees a refund of up to 90% of the treatment costs if the financial plan underestimates the costs to become pregnant.
  • "Boston IVF is pleased to offer the innovative Sunfish program to reduce the financial burden for patients," he states.
  • Sunfish is not a registered financial planner or advisor, lender, insurer, medical or healthcare provider and does not provide medical advice.

Ovation Research Included in Four Abstracts Selected for Presentation at ESHRE 2023

Retrieved on: 
Thursday, June 29, 2023

Nashville, June 29, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility scientists contributed to four pieces of research accepted for poster presentation at the ESHRE virtual 39th Annual Meeting.

Key Points: 
  • Nashville, June 29, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility scientists contributed to four pieces of research accepted for poster presentation at the ESHRE virtual 39th Annual Meeting.
  • The event, hosted by the European Society of Human Reproduction and Embryology, was held this year in Copenhagen, Denmark, June 25-28, 2023.
  • “The Ovation scientific team is incredibly excited about the opportunity to present our collaborative efforts and works in Copenhagen this year,” says Ovation Vice President of Scientific Advancement Matthew “Tex” VerMilyea, PhD, HCLD/CC.
  • Ovation recently joined US Fertility, the nation’s largest partnership of physician-owned fertility practices, to create the leading fertility platform in the United States.

Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

Retrieved on: 
Tuesday, June 27, 2023

Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.

Key Points: 
  • Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.
  • Therefore, a successful oral FSHR drug must stimulate the FSH receptor without stimulating the thyroid hormone receptor (TSHR).
  • Early Celmatix data suggests that their unique, rationally designed compounds overcome this significant hurdle to drug development for this target.
  • Celmatix Chief Scientific Officer, Dr. Stephen Palmer, notes, “We are very pleased to see that several of our novel compounds demonstrate the desired potency and selectivity required for a successful oral FSH drug.

Instituto Bernabeu creates the first AI International Unit applied to Reproductive Medicine

Retrieved on: 
Wednesday, June 7, 2023

After a recognized research trajectory in the use of Artificial Intelligence, Instituto Bernabeu has just created the first International Unit specialized in AI applied to Reproductive Medicine.

Key Points: 
  • After a recognized research trajectory in the use of Artificial Intelligence, Instituto Bernabeu has just created the first International Unit specialized in AI applied to Reproductive Medicine.
  • "This world-first unit is the result of our Scientifics successful work in the AI field in recent years.
  • Thanks to AI, these patients' diagnosis and prognosis will significantly improve", points out the IB Group's medical co-director Andrea Bernabeu.
  • Among the members of this new unit, highly skilled and renowned specialists in the different areas stand out: Instituto Bernabeu Mallorca medical director, Dr. Jordi Suñol; Instituto Bernabeu Group Embryology Unit director, Dr. Jorge Ten; Congenital Defects Unit director, the biochemist Dr. José Antonio Ortiz; and Instituto Bernabeu Madrid Embryology director, Leyre Herrero.